“Tylenol during pregnancy linked to autism and ADHD”

• Multiple large observational cohort studies have reported statistically significant associations between prenatal acetaminophen (paracetamol/Tylenol) exposure and later ADHD or autism diagnoses in offspring. Liew et al. (JAMA Pediatrics, 2014), using the Danish National Birth Cohort (~64,000 children), found prenatal acetaminophen use associated with higher risk of hyperkinetic disorder and ADHD medication use (hazard ratios ~1.3-1.4), with stronger associations for longer duration of use.
• A biomarker-based study (Ji et al., JAMA Psychiatry, 2020) measured acetaminophen metabolites in umbilical cord plasma in the Boston Birth Cohort and found that children in the highest exposure tertile had roughly 2-3 times the odds of ADHD and autism diagnoses compared with the lowest tertile — evidence not dependent on maternal self-report recall.
• A 2021 Consensus Statement by 91 scientists and clinicians published in Nature Reviews Endocrinology (Bauer et al.) reviewed the epidemiological and experimental literature and called for precautionary action, concluding acetaminophen is a suspected endocrine disruptor with possible neurodevelopmental effects.
• In September 2025 the U.S. FDA announced it would initiate a label change for acetaminophen regarding use in pregnancy, and HHS leadership publicly asserted a link to autism — an official action that gave the claim institutional backing.
• The word 'linked' in the claim is the weakest possible causal term; in the narrow sense that peer-reviewed studies have reported associations, the statement is literally accurate.
• Some meta-analyses and umbrella reviews (e.g., Alemany et al. 2021 European Journal of Epidemiology; 2025 umbrella reviews) report pooled associations in the range of ~1.2-1.3 relative risk for ADHD and autism, with suggestions of a dose-response pattern.

• The largest and best-controlled study to date — Ahlqvist et al. (JAMA, 2024), covering 2.48 million Swedish children — found a small association in the full population (e.g., ~1.05-1.07 hazard ratios) that disappeared entirely in sibling-control analyses (autism HR 0.98, ADHD HR 0.98, intellectual disability HR 1.01). Sibling comparison controls for shared genetics and family environment, strongly suggesting the association is confounded rather than causal.
• Confounding by indication is a major problem: women take acetaminophen for fever, infection, pain, migraine and chronic conditions — several of which (maternal infection/fever, chronic pain, inflammation) are themselves independently associated with neurodevelopmental outcomes. Studies rarely isolate the drug from the reason for taking it.
• Genetic confounding is substantial: autism and ADHD are highly heritable (~60-80%), and parental traits such as ADHD and chronic pain conditions predict both analgesic use and offspring diagnoses.
• Most positive studies rely on maternal self-reported, retrospectively recalled use, with no dosing data, and effect sizes are small (typically RR 1.1-1.3) — within the range commonly produced by residual confounding in observational epidemiology.
• Professional bodies have publicly rejected the causal framing. The American College of Obstetricians and Gynecologists stated there is no clear evidence of a direct causal relationship and that acetaminophen remains one of the few safe analgesic/antipyretic options in pregnancy; similar positions have been issued by the Society for Maternal-Fetal Medicine, the UK MHRA/NHS, the European Medicines Agency, and the WHO.
• Even the FDA's own 2025 label-change notice and its earlier 2015 Drug Safety Communication acknowledge that a causal relationship has not been established and that the evidence is too limited to support a definitive conclusion.
• Untreated high fever and severe pain in pregnancy carry documented risks (including neural tube defects and preterm birth), so the implied advice to avoid acetaminophen can itself cause harm — and NSAIDs/aspirin are contraindicated in much of pregnancy.
• Autism diagnosis rates have risen for well-documented reasons (broadened diagnostic criteria, screening, awareness) that do not track acetaminophen consumption patterns, undermining ecological arguments for causation.

82/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMA (via PubMed) — Ahlqvist et al., 'Acetaminophen Use During Pregnancy and Children's Risk of Autism, ADHD, and Intellectual Disability'journal · 96 · JAMA — Ahlqvist et al. 2024 (sibling-control cohort, 2.48M children)journal · 96 · JAMA Psychiatry — Ji et al., cord-plasma acetaminophen biomarkers and ADHD/ASDjournal · 88 · JAMA Pediatrics — Liew et al., Danish National Birth Cohort, acetaminophen and hyperkinetic/ADHD outcomesjournal · 85 · Nature Reviews Endocrinology — Bauer et al., 'Paracetamol use during pregnancy — a call for precautionary action'journal · 85 · American College of Obstetricians and Gynecologists — statements on acetaminophen use in pregnancyother · 88 · NHS (UK) — paracetamol in pregnancy guidancegov · 90 · FactCheck.org — coverage of acetaminophen/autism claims (Sept 2025)factcheck · 85

• Several observational cohort studies and meta-analyses have reported a modest statistical association between prenatal acetaminophen/paracetamol exposure and later ADHD or autism-spectrum outcomes. This supports the word "linked" if it is understood as correlation, not proven causation.
• A 2018 American Journal of Epidemiology meta-analysis found cohort-study evidence associating prenatal acetaminophen exposure with increased risk of ADHD and autism-spectrum disorder, though the authors noted observational limitations.
• A JAMA Psychiatry study using umbilical-cord biomarkers found higher fetal acetaminophen exposure biomarkers were associated with later ADHD and autism-spectrum diagnoses, reducing—but not eliminating—concerns about inaccurate maternal self-report.
• Some studies report stronger associations with longer duration or more frequent acetaminophen use in pregnancy, which is one reason researchers have continued to investigate a possible relationship.

• The best available evidence does not establish that Tylenol/acetaminophen causes autism or ADHD. Observed associations may reflect confounding by indication: fever, infection, inflammation, pain, genetics, or family-level factors that led to acetaminophen use and also affect neurodevelopmental risk.
• A large 2024 JAMA Swedish nationwide cohort found small associations in ordinary population analyses, but those associations disappeared in sibling-comparison analyses, suggesting familial/genetic or environmental confounding rather than a causal acetaminophen effect.
• The FDA has reviewed the evidence and said available studies are limited and do not allow a reliable conclusion that acetaminophen use in pregnancy causes ADHD or other neurobehavioral outcomes.
• ACOG states that there is no clear evidence proving a direct relationship between prudent acetaminophen use during pregnancy and fetal developmental issues, and it continues to regard acetaminophen as an important option when clinically needed.
• MotherToBaby notes that some studies suggest possible links with ADHD/autism-related outcomes, but limitations make it unclear whether acetaminophen, the conditions being treated, or other factors explain the findings.

86/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMAjournal · 96 · American Journal of Epidemiologyjournal · 90 · JAMA Psychiatryjournal · 90 · JAMA Pediatricsjournal · 88 · American College of Obstetricians and Gynecologistsother · 86 · MotherToBaby / NCBI Bookshelfgov · 86 · Nature Reviews Endocrinologyjournal · 78

• Numerous observational epidemiological studies and meta-analyses over the past decade have shown a statistical association (a 'link') between maternal use of acetaminophen (Tylenol) during pregnancy and an increased risk of neurodevelopmental disorders, such as ADHD and autism spectrum disorder (ASD), in children.
• A prominent 2019 study funded by the National Institutes of Health (NIH) analyzed umbilical cord blood biomarkers and found that in utero exposure to acetaminophen was associated with significantly higher risks of childhood ADHD and autism.
• In 2021, a consensus statement supported by 91 scientists and published in Nature Reviews Endocrinology warned that paracetamol (acetaminophen) exposure during pregnancy might alter fetal development and called for precautionary warnings for pregnant women.

• Medical authorities emphasize that an observational 'link' does not equal causation. The American College of Obstetricians and Gynecologists (ACOG) maintains that these studies likely suffer from 'confounding by indication,' meaning the underlying conditions prompting the Tylenol use (such as high maternal fever or severe pain) may be the actual culprits affecting fetal development.
• The U.S. Food and Drug Administration (FDA) has repeatedly reviewed the evidence and concluded that the studies are too inconclusive to warrant changing recommendations, affirming that acetaminophen remains a safe option for pregnant women when used appropriately.
• Recent large-scale research using sibling controls (which accounts for unmeasured genetic and environmental similarities) found no evidence of a causal relationship. A massive 2024 cohort study demonstrated that once sibling data was factored in, the increased risk of autism and ADHD completely disappeared.
• In December 2023, a U.S. federal judge dismissed thousands of mass tort lawsuits claiming Tylenol caused autism and ADHD, ruling that the plaintiffs' expert scientific testimony on causation lacked rigorous scientific methodology and was therefore inadmissible.

95/100 — the lab’s own confidence in the score above, not a second reading of the claim.

National Institutes of Health (NIH)gov · 95 · Nature Reviews Endocrinologyjournal · 90 · American College of Obstetricians and Gynecologists (ACOG)other · 95

• Several observational studies and meta-analyses have reported modest associations between prenatal acetaminophen exposure and later ADHD or autism diagnoses. One 2025 meta-analysis reported pooled odds ratios of 1.30 for ADHD and 1.17 for autism spectrum disorder, although the analyses showed important heterogeneity and observational-study limitations. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12436899/]
• The U.S. Food and Drug Administration stated in 2025 that evidence had accumulated suggesting an association between acetaminophen use during pregnancy and neurological conditions such as autism and ADHD, and began a label-change process. The FDA explicitly described this as an association, not proof of causation. [https://www.fda.gov/news-events/press-announcements/fda-responds-evidence-possible-association-between-autism-and-acetaminophen-use-during-pregnancy]
• The U.S. Department of Health and Human Services cited large cohort studies reporting associations between in-utero exposure and later autism or ADHD diagnoses. [https://www.hhs.gov/press-room/autism-announcement-fact-sheet.html]

• The FDA states that a causal relationship between prenatal acetaminophen exposure and autism or ADHD has not been established and notes that contrary studies exist. [https://www.fda.gov/news-events/press-announcements/fda-responds-evidence-possible-association-between-autism-and-acetaminophen-use-during-pregnancy]
• The World Health Organization states that there is currently no conclusive scientific evidence confirming a link between autism and acetaminophen use during pregnancy. [https://www.who.int/news/item/24-09-2025-who-statement-on-autism-related-issues]
• A 2025 systematic review and meta-analysis concluded that existing evidence does not clearly link maternal paracetamol use during pregnancy with autism or ADHD, and that the evidence is insufficient to establish a definitive connection. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12838471/]
• A large Swedish nationwide cohort using sibling comparisons found no significant association between prenatal acetaminophen exposure and autism, ADHD, or intellectual disability, suggesting that earlier associations may reflect confounding or methodological bias. [https://pmc.ncbi.nlm.nih.gov/articles/PMC13408299/]
• A separate systematic review reported no association in sibling-comparison studies for autism or ADHD, and no association in studies judged to have low risk of bias. [https://publichealth.washu.edu/app/uploads/2026/01/Prenatal-paracetamol-exposure-and-child-neurodevelopment.pdf]
• The American College of Obstetricians and Gynecologists reviewed the evidence as part of its 2025 guidance, reflecting that the issue remains one of interpretation of observational evidence rather than an established causal relationship. [https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2025/09/acetaminophen-use-in-pregnancy-and-neurodevelopmental-outcomes]

91/100 — the lab’s own confidence in the score above, not a second reading of the claim.

U.S. Food and Drug Administrationgov · 98 · World Health Organizationgov · 98 · American College of Obstetricians and Gynecologistsedu · 95 · Systematic review indexed in PubMed Centraljournal · 88 · Systematic review and meta-analysis indexed in PubMed Centraljournal · 84 · Peer-reviewed cohort study indexed in PubMed Centraljournal · 90 · Systematic review and meta-analysis hosted by Washington University School of Medicinejournal · 90 · U.S. Department of Health and Human Servicesgov · 92

• Observational cohort studies and meta-analyses have reported statistical associations between prenatal acetaminophen exposure and higher subsequent rates of ASD and ADHD diagnoses, sometimes with apparent duration/dose gradients.
• A 2021 consensus statement by 91 scientists in Nature Reviews Endocrinology described the associative evidence as sufficient to warrant precautionary steps around use in pregnancy and called for more research.

• A 2024 nationwide Swedish sibling-comparison study of ~2.5 million children (JAMA) found no increased risk of autism, ADHD, or intellectual disability after accounting for familial confounding, indicating earlier signals were likely not causal.
• FDA (2015 review, still operative) and ACOG have stated the data are limited/inconclusive for causation and continue to list acetaminophen as the preferred analgesic/antipyretic in pregnancy; underlying indications (fever, infection, pain) and genetics are plausible confounders.
• No proven mechanism, no randomized evidence, and small absolute risks even in positive observational papers; professional guidance does not recommend avoidance when clinically indicated.

84/100 — the lab’s own confidence in the score above, not a second reading of the claim.

JAMAjournal · 96 · Nature Reviews Endocrinologyjournal · 93 · American College of Obstetricians and Gynecologistsother · 88